Oncology Search
Oncology Oncology
multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Darzalex
daratumumab

Indication: In combination w/ lenalidomide or bortezomib & dexamethasone for multiple myeloma in patients who have rec...

Indication: Anemia associated w/ chronic renal failure in adults & paed on dialysis. Anemia & reduction of transfu...

Indication: Agammaglobulinemia/hypogammaglobulinemia. Combined therapy w/ antibiotics in severe bacterial or viral infecti...

Indication: Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has pro...

Indication: Multiple myeloma. Mantle cell lymphoma in patients who have received at least 1 prior therapy.

Indication: Multiple myeloma & mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy.

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Tab: Multiple myeloma, advanced ovarian adenocarcinoma, breast carcinoma, polycythaemia rubra vera. Inj: Local...

Indication: Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; rel...

1  /  5
1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Chemo alone remains SOC for locally advanced endometrial cancer
Roshini Claire Anthony, 08 Jul 2019

The addition of radiation therapy to chemotherapy does not provide a relapse-free survival (RFS) advantage over chemotherapy only in stage III or IVA endometrial cancer, according to the phase III GOG 258* trial.
BRCA2 mutations associated with oesophageal squamous cell carcinoma risk in Chinese
Natalia Reoutova, 2 days ago
A recently published study involving 4,517 individuals confirmed the role of BRCA2 mutations in genetic predisposition to oesophageal squamous cell carcinoma (OSCC) among Chinese.
Metformin does not prevent cancer in diabetic patients
10 Aug 2019
Treatment with metformin does not appear to provide an additional benefit of reducing the incidence of cancers, excluding those of the prostate and pancreas, in patients with diabetes, as reported in a study.